Table 2.
IRC- and INV-assessed response rates at EOI (lenalidomide 20 mg cohort, n = 32 evaluable patients; primary analysis).
| PET-CT scan (modified Lugano 2014) | CT-MRI scan (Lugano 2014) | |||
|---|---|---|---|---|
| IRC-assessed | Patients, n (%) | 90% CI | Patients, n (%) | 90% CI |
| ORR | 25 (78.1) | 62.8–89.3 | 26 (81.3) | 66.3–91.5 |
| CR | 23 (71.9) | 56.1–84.5 | 10 (31.3) | 18.0–47.2 |
| PR | 2 (6.3) | 16 (50.0) | ||
| SD | 2 (6.3) | 1 (3.1) | ||
| PD | 3 (9.4) | 4 (12.5) | ||
| INV-assessed | ||||
|---|---|---|---|---|
| ORR | 27 (84.4) | 69.9–93.6 | 28 (87.5) | 73.6–95.6 |
| CR | 24 (75.0) | 59.4–86.9 | 16 (50.0) | 34.4–65.6 |
| PR | 3 (9.4) | 12 (37.5) | ||
| SD | 1 (3.1) | 1 (3.1) | ||
| PD | 1 (3.1) | 1 (3.1) | ||
CR complete response, CT computed tomography, EOI end of induction, INV investigator, IRC independent review committee, MRI magnetic resonance imaging, ORR objective response rate, PD progressive disease, PET positron emission tomography, PR partial response, SD stable disease.